Showing results (221-230 of 456) with videos related to
Sort By:
Pageof 46
Cancer|March 26, 2003
Can patient selection for bladder preservation be based on response to chemotherapy?Cora N Sternberg, Vito Pansadoro, Fabio Calabrò, et al.Frontiers in Oncology|November 29, 2012
An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumorsEugenio Donato Di Paola, Silvia Alonso, Rosa Giuliani, et al.BJU International|January 4, 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatmentAndrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, et al.The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.European Urology|April 18, 2001
Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patientsS G Williams, R Gandour-Edwards, A D Deitch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapyMatthew D Galsky, Noah M Hahn, Jonathan Rosenberg, et al.Japanese Journal of Clinical Oncology|March 19, 2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive diseaseHiroyoshi Suzuki, Daniel Castellano, Johann de Bono, et al.JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.Pageof 46